DGIdb - THALIDOMIDE Drug Record

THALIDOMIDE chembl:CHEMBL468 ApprovedAntineoplasticImmunotherapy

Alternate Names:

TALIDEX
K-17
THALIDOMIDE
NSC-66847
NSC-527179
THALOMID
THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Α-(N-PHTHALIMIDO)GLUTARIMIDE
(±)-THALIDOMIDE
Α-PHTHALIMIDOGLUTARIMIDE
(+-)-THALIDOMIDE
TALIDOMIDA
Α-N-PHTHALYLGLUTARAMIDE
N-PHTHALYL-GLUTAMINSAEURE-IMID
N-PHTHALYLGLUTAMIC ACID IMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
3-PHTHALIMIDOGLUTARIMIDE
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
THALIDOMIDUM
N-PHTHALOYLGLUTAMIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
drugbank:01041
chembl:CHEMBL468
rxcui:10432
pubchem.compound:5426
chemidplus:50-35-1

Drug Info:

Drug Categories	growth inhibitors
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Year of Approval	approved before 1982
Drug Class	leprostatic agents
Drug Class	immunosuppressive agents
Drug Categories	cardiotoxic antineoplastic agents
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a inducers
Drug Categories	cytochrome p-450 cyp3a5 inducers
Drug Categories	cytochrome p-450 cyp3a5 inducers (strength unknown)
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	decreased immunologically active molecule activity
Drug Categories	drugs causing inadvertant photosensitivity
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	immunomodulatory agents
Drug Categories	photosensitizing agents

(5 More Sources)

Publications:

Vacca et al., 2005, Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma., J. Clin. Oncol.
Deeken JF et al., 2010, A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform., Pharmacogenomics J
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Yasui et al., 2005, Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation., Curr. Pharm. Des.
Horrobin, 2003, A low toxicity maintenance regime, using eicosapentaenoic acid and readily available drugs, for mantle cell lymphoma and other malignancies with excess cyclin D1 levels., Med. Hypotheses
Hada et al., 2004, [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]., Gan To Kagaku Ryoho
Du et al., 2005, Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis., Vascul. Pharmacol.
Kim et al., 2011, Thalidomide: the tragedy of birth defects and the effective treatment of disease., Toxicol. Sci.
Payvandi et al., 2004, Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner., Cell. Immunol.
Wiedmann et al., 2005, Molecularly targeted therapy for gastrointestinal cancer., Curr Cancer Drug Targets
Zhu et al., 2013, Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma., Leuk. Lymphoma
Turk et al., 1996, Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production., Proc. Natl. Acad. Sci. U.S.A.
Richardson et al., 2002, Thalidomide in multiple myeloma., Biomed. Pharmacother.
Vescovo et al., 2002, Effect of thalidomide on the skeletal muscle in experimental heart failure., Eur. J. Heart Fail.
Enomoto et al., 2002, Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production., Gastroenterology
Fu et al., 2002, Thalidomide and tuberculosis., Int. J. Tuberc. Lung Dis.
Rajkumar, 2001, Thalidomide in the treatment of multiple myeloma., Expert Rev Anticancer Ther
do Socorro Silva Costa P et al., 2019, <i>NR3C1</i>, <i>ABCB1</i>, <i>TNF</i> and <i>CYP2C19</i> polymorphisms association with the response to the treatment of erythema nodosum leprosum., Pharmacogenomics
Minnema et al., 2003, Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment., J. Thromb. Haemost.
Li et al., 2002, [Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients]., Zhonghua Zhong Liu Za Zhi
Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs
Eichholz et al., 2010, Anti-angiogenesis therapies: their potential in cancer management., Onco Targets Ther
Tsambaos et al., 1994, Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene., Arch. Dermatol. Res.
Cibeira MT et al., 2011, Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide., Leuk Res
Kaushal et al., 2004, Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology., J. Thromb. Haemost.
Shannon et al., 1994, Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential., Immunopharmacol Immunotoxicol
Wróbel T et al., 2017, <i>bFGF</i> Polymorphism Is Associated with Disease Progression and Response to Chemotherapy in Multiple Myeloma Patients., Anticancer Res
Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res
Juffermans et al., 2000, Thalidomide suppresses Up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4+ T cells in humans., J. Infect. Dis.
Settles et al., 2001, Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide., Cell. Mol. Biol. (Noisy-le-grand)

THALIDOMIDE SNORD68

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE SPG7

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE RPL13

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE SULT1C4

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE CHST3

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE CYP4B1

Interaction Score: 1.58

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE CRBN

Interaction Score: 1.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Binding

PMIDs:
22966948

Sources:
DrugBank GuideToPharmacology ChemblInteractions
THALIDOMIDE ABCC6

Interaction Score: 0.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE XRCC5

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21435719

Sources:
PharmGKB
THALIDOMIDE DDB1

Interaction Score: 0.53

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
THALIDOMIDE CUL4A

Interaction Score: 0.53

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
THALIDOMIDE SLC10A2

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE ORM1

Interaction Score: 0.53

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
8755512

Sources:
DrugBank
THALIDOMIDE ATP7A

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE IL6R

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12515619

Sources:
NCI
THALIDOMIDE GSTT1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21435719

Sources:
PharmGKB
THALIDOMIDE RBX1

Interaction Score: 0.26

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
THALIDOMIDE VWF

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12871448

Sources:
NCI
THALIDOMIDE TNF

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Thalomid

PMIDs:
8755512 12046682 12167383 12105857 12102294 11752352 12113124

Sources:
TEND TdgClinicalTrial TTD DrugBank
THALIDOMIDE F2R

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14995997

Sources:
NCI
THALIDOMIDE ERCC1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21435719

Sources:
PharmGKB
THALIDOMIDE HGF

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15939924

Sources:
NCI
THALIDOMIDE CTLA4

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10823791

Sources:
NCI
THALIDOMIDE NAT2

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE ITGB2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11838958

Sources:
NCI
THALIDOMIDE CTNNB1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26521987

Sources:
PharmGKB
THALIDOMIDE FGF2

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28373444

Sources:
PharmGKB
THALIDOMIDE HLA-B

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7876469

Sources:
NCI
THALIDOMIDE FGFR2

Interaction Score: 0.11

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Thalomid

Novel drug target Established target

PMIDs:
20616958

Sources:
TEND TdgClinicalTrial DrugBank
THALIDOMIDE FCGR3B

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15457133

Sources:
NCI
THALIDOMIDE PTGS2

Interaction Score: 0.1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Thalomid

Novel drug target Established target

PMIDs:
12710892 15446566 15982930 21507989 15598423 15892618

Sources:
TdgClinicalTrial DrugBank
THALIDOMIDE FCGR3A

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15457133

Sources:
NCI
THALIDOMIDE NFKB1

Interaction Score: 0.08

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name Thalomid

Novel drug target Established target

PMIDs:
11752352 15723633

Sources:
TEND TdgClinicalTrial DrugBank
THALIDOMIDE PPARD

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
THALIDOMIDE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31124417

Sources:
PharmGKB
THALIDOMIDE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7979550

Sources:
NCI

DrugBank: DB01041

Version: 5.1.7

Alternate Names:

50-35-1 CAS Number

Contergan Drug Brand

Distaval Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Stephens et al., 2000, Mechanism of action in thalidomide teratogenesis., Biochem. Pharmacol.

Stephens et al., 2000, Hypothesis: thalidomide embryopathy-proposed mechanism of action., Teratology

Shoji et al., 2007, Modified DNA aptamer that binds the (R)-isomer of a thalidomide derivative with high enantioselectivity., J. Am. Chem. Soc.

TEND: THALIDOMIDE
- Version: 01-August-2011
Alternate Names:

Drug Info:

Drug Class immunosuppressive agents

Drug Class leprostatic agents

Year of Approval approved before 1982

Publications:
TdgClinicalTrial: THALIDOMIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: THALIDOMIDE

Version: 14-September-2017

Alternate Names:

C870 NCI drug code

Drug Info:

Publications:

Vacca et al., 2005, Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma., J. Clin. Oncol.

Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs

Juffermans et al., 2000, Thalidomide suppresses Up-regulation of human immunodeficiency virus coreceptors CXCR4 and CCR5 on CD4+ T cells in humans., J. Infect. Dis.

PharmGKB: thalidomide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Deeken JF et al., 2010, A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform., Pharmacogenomics J

Cibeira MT et al., 2011, Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide., Leuk Res

Butrym A et al., 2015, Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment., Leuk Res

TTD: Thalidomide
- Version: 2020.06.01
Alternate Names:

D0U7GK TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL468
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL468
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
GuideToPharmacology: 178103899
- Version: 29-September-2020
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Binding

Mechanism of Interaction	CRL4(CRBN) E3 ubiquitin ligase inhibitor
Direct Interaction	yes

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

THALIDOMIDE Drug Record

THALIDOMIDE chembl:CHEMBL468 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Binding

PMIDs: 22966948

Sources: DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21435719

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: binder

Interaction Info:

PMIDs: 8755512

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12515619

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21435719

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12871448

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Thalomid

PMIDs: 8755512 12046682 12167383 12105857 12102294 11752352 12113124

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Binding

PMIDs:
22966948

Sources:
DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21435719

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

binder

PMIDs:
8755512

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12515619

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21435719

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction CRL4(CRBN) E3 ubiquitin ligase inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
12871448

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Thalomid

PMIDs:
8755512 12046682 12167383 12105857 12102294 11752352 12113124

Sources:
TEND TdgClinicalTrial TTD DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
14995997

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21435719

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15939924

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10823791

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11838958

Sources:
NCI